Treatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric G250

NCT00199875 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Renal Cell Carcinoma
Kidney Neoplasm
Renal Cancer
Kidney Cancer

Interventions

DRUG: Yttrium-90 conjugated chimeric G250 (^90Y-DOTA-cG250)

Sponsor

Ludwig Institute for Cancer Research

Collaborators

[object Object]